Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PGEN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Precigen Inc

PGEN
Current price
1.59 USD -0.02 USD (-1.24%)
Last closed 1.62 USD
ISIN US74017N1054
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 478 191 616 USD
Yield for 12 month +2.58 %
1Y
3Y
5Y
10Y
15Y
PGEN
21.11.2021 - 28.11.2021

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. Address: 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.13 USD

P/E Ratio

Dividend Yield

Financials PGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+3 925 000 USD

Last Year

+6 225 000 USD

Current Quarter

+1 341 000 USD

Last Quarter

+1 190 000 USD

Current Year

-342 000 USD

Last Year

+106 000 USD

Current Quarter

+241 000 USD

Last Quarter

+21 000 USD
EBITDA -89 331 000 USD
Operating Margin TTM -1 685.01 %
Price to Earnings
Return On Assets TTM -44.04 %
PEG Ratio
Return On Equity TTM -278.55 %
Wall Street Target Price 6.13 USD
Revenue TTM 4 201 000 USD
Book Value -0.048 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 25.90 %
Dividend Yield
Gross Profit TTM -53 161 000 USD
Earnings per share -0.55 USD
Diluted Eps TTM -0.55 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation PGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 9.14
Enterprise Value Revenue 95.67
Price Sales TTM 113.83
Enterprise Value EBITDA -3.31
Price Book MRQ 7.25

Technical Indicators PGEN

For 52 Weeks

0.65 USD 2.17 USD
50 Day MA 1.44 USD
Shares Short Prior Month 27 625 665
200 Day MA 1.26 USD
Short Ratio 15.46
Shares Short 27 281 305
Short Percent 16.04 %